Day One, 15th March 2016 08.00
Registration & Coffee
08.20
Welcome Speech
08.30
Public Markets and M&A Panel Chaired by: Stephanie Léouzon, Partner and Head of Europe, Torreya Partners (Europe) LLP Panellists: Adam Kostyál, Senior Vice President, NASDAQ OMX Ajan Reginald, Chief Executive Officer, Cell Therapy Ltd. Christian Lach, Portfolio Manager, Bellevue Asset Management AG Ivo Staijen, Investment Advisor, Portfolio Manager, HBM Partners AG James Sapirstein, CEO, ContraVir Pharmaceuticals Raffaele Petrone, Chairman of Board of Directors and CEO, Therametrics Thomas Stockman, Director, Healthcare Investment Banking, Royal Bank of Canada
09.30
Investment Panel Co-chaired by: Markus Goebel, Managing Director, Novartis Venture Fund Markus Hosang, General Partner and Managing Director, BioMedPartners AG Panellists: Arthur Franken, Partner, Gilde Healthcare Cynthia Lavoie, General Partner, TVM Life Science Management, Inc. Lionel Carnot, Managing Director, Bay City Capital Margarita Chavez, Director, Ventures & Early Stage Collaborations, AbbVie Inc. Matthew Foy, Partner, S.R.One, Limited Michèle Ollier, Partner, Medicxi Ventures Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners Paul Hermant, Partner, Bird & Bird LLP
Track A Moderated by: Joergen Thorball 09.30
DC4U B.V.
09.40
Glide Pharmaceutical Technologies Limited
09.50
Marinomed Biotechnologie GmbH
10.00
[Available]
10.10
ATRIVA Therapeutics GmbH
10.20
EMTensor GmbH
10.30
Coffee Break
10.45
Oncology I – Clinical Development and Regulation in Europe Co-Chaired by: Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics François Thomas, President, Inserm Transfert Initiative Panellists: Eugen Leo, Senior Consultant, LEO Consulting Heinz Lubenau, General Manager and Head of Development, VAXIMM GmbH Laurent Audoly, Senior Vice President R&D, Global Head of Drug Development and Translational Medicine, Institut de Recherche Pierre Fabre Mark Vaeck, CEO, Complix NV Richard Godfrey, CEO, BerGenBio AS Simon Kerry, Chief Executive Officer, Karus Therapeutics Ltd.
11.45
12.30
Oncology II - Innovation and BD&L Co-Chaired by: Esteban Pombo-Villar, Chief Operating Officer, Oxford BioTherapeutics Tim Herpin, Vice President, Head of Transactions (UK), AstraZeneca Panellists: Anja König, Managing Director, Novartis Venture Fund David Malek, VP Business Development, BioLineRx Guillaume Vignon, Director Business Development Oncology - Global Business Development and Licensing, EMD Serono Peter Hoang, Senior Vice President Business Development & Strategy, Bellicum Pharmaceuticals, Inc. Jason Slingsby, Head of Business Development, Oxford BioMedica
Track B Moderated by: Hans Herklots
10.45
11.30
Interview with Pierre Fabre Fund for Innovation by: Fintan Walton, CEO, PharmaVentures Ltd.
12.15 12.45
13.00
TBA
Networking Lunch
Curetis N.V.
10.55
InnVentis Ltd.
11.05
Provista Diagnostics, Inc.
Diagnostics & Imaging Panel Chaired by: Beat Merz, Managing Director, Rockport Venture Partners Panellists: Ena Prosser, Partner, Fountain Healthcare Partners David Reese, President and CEO, Provista Diagnostics, Inc. Oliver Schacht, CEO, Curetis N.V. Rainer Metzger, Vice Precident, Head Precision Diagnostics and Pharma Partnering, QIAGEN GmbH Thierry Chignon, Senior Partner, Merieux Developpement Thomas Wilckens, CEO, InnVentis Ltd.
Autoimmune & Infectious Diseases Panel Chaired by: Regina Hodits, General Partner, Wellington Partners Panellists: Dale Dhanoa, CEO, AKAAL Pharma Eric de La Fortelle, Venture Partner, Seventure Partners Markus Kalousek, Global BD&L Franchise Head, I&D, S&E, Novartis Pharma AG Simon Blake, Senior Director, Scientific Licensing for Immunology, Janssen Pharmaceuticals Research and Development
Track C
10.45
Targovax ASA
11.00
ContraVir Pharmaceuticals, Inc.
11.15
Addex Therapeutics Ltd.
11.30
Cell Therapy Ltd.
11.45
Tissue Regenix Group Plc.
12.00
Eos Biosciences, Inc.
12.15
Inventiva Pharma
12.30
[Available]
12.45
ImmunID
14.00
14.45
15.45
16.00
17.00
18.00
Platform Technologies & Novel Therapeutics Panel Co-Chaired by: Chandra Leo, Partner, HBM Partners AG Heinz Schwer, CEO, Lanthio Pharma B.V. Panellists: Anker Lundemose, CEO, MISSION Therapeutics Ltd. Christophe Bonny, CSO, Bicycle Therapeutics Limited David Urech, Co-CEO & CSO, Numab AG Dieter Ziegler, Director - Search and Evaluation Europe, AbbVie Inc. Mark Carnegie-Brown, CEO, Glide Technologies Innovation Panel Co-Chaired by: Matthias Bünte, Head Operational Transaction Services, Ernst & Young AG Rao Movva, Novartis Distinguished Scientist, Novartis Institutes for BioMedical Research Panellists: Bill Blair, Director of Company Creation, Sunergos Innovations Ernst Hafen, President, Bio-Technopark Schlieren-Zurich Fabian Buller, Director, New Ventures, Johnson & Johnson Innovation François Thomas, President, Inserm Transfert Initiative Joern-Peter Halle, SVP, Head of External Innovation, Biopharma, Global Research & Development, Merck KGaA Ulrich Muehlner, Global Head Outcomes Technologies Incubator (NOVAE), Novartis Coffee Break Neuroscience Panel Chaired by: Charles Bailey, Head of Search & Evaluation, Neurosciences, Novartis Pharma AG Panellists: Jennifer Laird, Senior Director, Search & Evaluation, Eli Lilly & Co. Klaus Mendla, Global Head, CNS BD and Licensing, Boehringer Ingelheim Pharma GmbH & Co. KG Laurence Barker, Dementia Discovery Fund Chief Business Officer, SV Life Sciences Pierandrea Muglia, Vice President, Head Neuroscience Discovery, UCB Pharma Rosa Sancho, Head of Research, Alzheimer's Research UK Tim Dyer, CEO, Addex Therapeutics Early Stage Investment Panel Chaired by Hakan Goker, Senior Investment Director, MS Ventures Panellists: Carina Schmidt, CEO, Athera Biotechnologies AB Jonathan Tobin, Principal, Healthcare Ventures, Imperial Innovations Karl Nägler, Partner, Gimv Lars Gredsted, Senior Business Analyst, Wellcome Trust Luc Otten, Business Development, The Alpine Institute for Drug Discovery Martin Pfister, Senior Investment Manager, High-Tech-Gruenderfonds Management GmbH Nanna Luneborg, Principal, Novo Ventures Reza Halse, Head of MSD European Innovation Hub, MSD Networking Reception
Track D Moderated by: Bob Pooler 14.00
OSE Pharma
14.15
BioLineRx Ltd.
14.30
Karus Therapeutics Ltd.
14.45
Avexxin AS
15.00
Helsinn Healthcare SA
15.15
[Reserved]
15.30
Track E Moderated by: Hans Herklots 14.00
amcure GmbH
14.10
BioSight Ltd.
14.20
INOFEA AG
14.30
Pragma Therapeutics
14.40
Therabron Therapeutics, Inc.
14.50
Athera Biotechnologies AB
15.00
GreenBone Ortho srl
15.10
Akinion Pharmaceuticals AB
15.25
[Reserved]
15.35
Virometix AG
Abzena PLC
Track F 16.00
Vaximm AG
16.15
Oxford BioMedica Plc.
16.30
BerGenBio AS
16.45
MISSION Therapeutics Ltd.
17.00
Numab AG
17.15
Bicycle Therapeutics Limited
17.30
Canbex Therapeutics Ltd.
17.45
[Available]
Track G 16.00
APIM Therapeutics AS
16.10
[Reserved]
16.20
Akaal Pharma Pty Ltd.
16.30
Inflamalps SA
16.40
Strekin AG
16.50
TaiwanJ Pharmaceuticals
17.00
Zytoprotec GmbH
17.10
[Available]
17.20 17.30
[Available] [Available]
17.40
[Available]
17.50
[Available]
Day Two, 16th March 2016
08.00
09.00
Registration & Coffee
Partnering Panel Session I – “How to win the big deal with pharmaceutical companies in a competitive market” Co-Chaired by: David Colpman, Director, Colpman Consulting Ltd. Fintan Walton, CEO, PharmaVentures Ltd. Panellists: Lubor Gaal, Head of Licensing and External Innovation, Almirall, S.A. Martin E. Judge, Innovation Sourcing Director, Novo Nordisk Paola Casarosa, Corp. VP, Business Development & Licensing/Prescription Medicines, Boehringer Ingelheim GmbH Patrick Benz, Senior Director Alliance Management, Johnson & Johnson Innovation/JBD Witte Uwe Schoenbeck, SVP & Chief Scientific Officer, External R&D, Pfizer
09.45
Partnering Panel Session II – “The art of creative deal structures in licensing and partnering agreements” Co-Chaired by: Chris Britten, Managing Director, Torreya Partners (Europe) LLC Fintan Walton, CEO, PharmaVentures Ltd. Panellists: Ivana Magovcevic-Liebisch, Senior Vice President and Head of Global Business Development, Teva Pharmaceutical Industries, Ltd. Norbert Steinbach, Director Business Development Western Europe & Canada, AbbVie Inc. Sarah Holland, Head of Europe, External Science and Partnering, Sanofi Sandra Nobre, Senior Director Business Development, Takeda Pharmaceuticals International Stewart Kay, Director, Business Development, GSK
10.30
“Secure Data for Biopharmaceutical Companies” – presentation by Luisa Henk, Senior Manager Business Development, Drooms AG
10.45
Coffee Break
Track A Moderated by: Joergen Thorball 09.45
ProAxsis Ltd.
09.55
Stratpharma AG
10.05 10.15
Medimetrics Personalized Drug Delivery B.V. MyoPowers Medical Technologies France SAS
10.25
Genetics Microdevices Ltd.
10.35
seiratherm GmbH
11.00
Track B
“AM-Pharma – Pfizer: A Collaboration Preparing for Success” Erik van den Berg, CEO, AM-Pharma Uwe Schoenbeck, SVP & Chief Scientific Officer, External R&D, Pfizer 11.00
Provectus Biopharmaceuticals, Inc.
11.15
Sophia Genetics
11.30
Anteo Diagnostics Ltd.
11.45
Xeltis AG
12.00
Speech: “Top Stories and Technologies to Watch in Medtech” by: David Cassak, Managing Partner, Innovation in Medtech, LLC Stephen Levin, Managing Partner, Innovation in Medtech, LLC
12.00
Vaxart, Inc.
12.15
MorphoSys AG
12.20
MedTech and Digital Health Panel Co-Chaired by: David Cassak, Managing Partner, Innovation in Medtech, LLC Stephen Levin, Managing Partner, Innovation in Medtech, LLC Panellists: Bart de Witte, Government & Healthcare Leader CEE, IBM Christoph Kausch, CEO, MTID MedTech Innovation Partners AG Eric Rambeaux, CEO, MyoPowers Medical Technologies France SAS Geoff Cumming, CEO, Anteo Diagnostics Limited Jennifer McMahon, Associate, Seroba Life Sciences Peter Langkafel, CEO, HCB Healthcubator GmbH Yves Decadt, CEO, Medimetrics Personalized Medicine
12.30
InGeneron GmbH
12.45
[Available]
11.15
13.00
Israel Panel Chaired by: Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences Panellists: Dan Gelvan, Managing Director, Aurum Ventures MKI Ltd. Ittai Harel, Managing General Partner, Pitango Venture Capital Michal Silverberg, Senior Director, External Innovations Israel and Europe, Takeda Pharmaceuticals Ruth Ben Yakar, CEO, BioSight Ltd.
Networking Lunch Workshop: "How to win or avoid IP and licensing disputes. - An assessment of mistakes made by losers”
14.00 Workshop leaders: Fintan Walton, CEO and Nigel Borshell, VP at PharmaVentures Ltd. 15.30
Last Chance To Network
16.00
End of The Forum
